Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared a post on X:
“TIL therapy + pembrolizumab (SEL-TIL + P) shows 23.5% response in mismatch repair–proficient GI cancers – where immunotherapy usually fails.
Neoantigen recognition may be the key.”
“Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial”
Authors:Frank J. Lowery et al.
